Merck (MRK) and Ridgeback Biotherapeutics Provide Update on New Studies of LAGEVRIO
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
| Merck & Co. (NYSE: MRK) | Delayed: 145.27 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $145.27 | 52 Week High | $65.46 | |||
| Open | $145.27 | 52 Week Low | $47.97 | |||
| Day High | $145.27 | P/E | 98.82 | |||
| Day Low | $145.27 | EPS | $1.47 | |||
| Volume | 6,296 | |||||
